Harvard Medical School spinout TScan has come out of stealth with $48m in funding provided by investors including GV and two Novartis units.

TScan Therapeutics, a US-based oncology drug spinout of Harvard University, emerged from stealth on Wednesday with $48m in funding from investors including internet and technology conglomerate Alphabet and pharmaceutical firm Novartis. The funding included a recent series B round of undisclosed size. The company’s investors include Alphabet unit GV and Novartis subsidiaries Novartis Venture Fund…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.